Monday, 27 February 2017

Dapoxetine Hcl Manufacturers



 Dapoxetine Hydrochloride Introduction:
 Dapoxetine hydrochloride belong to a class of drugs which is  known to be  selective serotonin reuptake inhibitors. Selective serotonin reuptake inhibitors is mainly used as antidepressants .It is  most widely prescribed in many countries. Dapoxetine hydrochloride is developed mainly for the treatment of premature ejaculation  in men.who are under the age group of 18-64 yrs.it is the  male sexual dysfunction.Dapoxetine is the fast acting medicine which is most suitable for the treatment of PE but it is not used for antidepressants. Different dosage has different impacts on different type of PE.So while taking these medicine consult the doctor.This medicine should be taken 1–3 hours before sexual episode.




Dapoxetine Hcl Manufacturers :
Rakshit drugs is an drug Intermediates manufacturer.We are located in Hyderabad. Our business is purely manufacturing and supplying of APIs with main focus to deliverables to our committed customer. we designed, equipped and operated our products mainly to deliver high quality products to customers. Environmental protection is also an integral part of our business.

Chemical Structure of Dapoxetine:
IUPAC name:(S)-N,N-Dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine
Formula: C21H23NO
Molar mass: 305.413 g/mol




Brand Name Of  Dapoxetine:
Dumax, Duratia, Kutub, Lejam, Pentenal-30, Priligy, Sustinex, and Westoxetin.

 Medication For Premature Ejaculation:
·        Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants such as Paroxetine,Escitalopram should be consumed weekly twice in order to get these good effect.
·        Dapoxetine is mainly developed for the treatment of premature ejaculation. It should not be consumed daily.It should be consumed 1-3 hours before you have sex.
·         Sildenafil should be sometimes consumed along with ssri in order for treatment of premature ejaculation
·        Local anaesthetic creams and sprays are available for prevention.










No comments:

Post a Comment